Newly diagnosed glioblastoma
Showing 1 - 25 of >10,000
Glioblastoma, IDH-wildtype Trial in Beijing (Elemene, Placebo)
Not yet recruiting
- Glioblastoma, IDH-wildtype
- Elemene
- Placebo
-
Beijing, ChinaPeking Union Medical College Hospital
Apr 22, 2023
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine
Recruiting
- Glioblastoma, IDH-wildtype
- +4 more
- Eflornithine (Dose Level 1)
- +3 more
-
Cleveland, OhioThe Cleveland Clinic
May 19, 2023
Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))
Active, not recruiting
- Glioblastoma
- Ibrutinib
- +2 more
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023
Newly Diagnosed Glioblastoma Trial (combinations of up to 3 FDA approved drugs from a panel of compounds)
Not yet recruiting
- Newly Diagnosed Glioblastoma
- combinations of up to 3 FDA approved drugs from a panel of compounds
- (no location specified)
Jan 19, 2023
Glioblastoma Trial in Boston (ITI-1001)
Not yet recruiting
- Glioblastoma
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 13, 2023
Glioblastoma, Newly Diagnosed Glioblastoma Trial in Stanford (device, drug, radiation)
Recruiting
- Glioblastoma
- Newly Diagnosed Glioblastoma
- Optune
- +3 more
-
Stanford, CaliforniaStanford University
Aug 1, 2022
Newly Diagnosed Glioblastoma Trial ([177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide)
Not yet recruiting
- Newly Diagnosed Glioblastoma
- [177Lu]Lu-NeoB
- +2 more
- (no location specified)
Feb 13, 2023
Glioblastoma Trial run by the NCI (drug, biological, other)
Completed
- Glioblastoma
- Pembrolizumab
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 23, 2022
Glioblastoma Multiforme of Brain Trial in Gatineau (avelumab)
Completed
- Glioblastoma Multiforme of Brain
- avelumab
-
Gatineau, Quebec, CanadaClinique Neuro-Outaouais
Jul 19, 2022
Newly Diagnosed Glioblastoma Patients
Recruiting
- Glioblastoma
- stressors
-
Zhengzhou, Henan, ChinaHenan Provincial People's Hospital
Aug 24, 2022
Malignant Tumor, Malignant Tumor of Brain Trial in Taiwan (NBM-BMX Capsule, Temozolomide, Standard radiotherapy)
Recruiting
- Malignant Neoplasm
- Malignant Neoplasm of Brain
- NBM-BMX Capsule
- +2 more
-
Hualien City, Taiwan
- +4 more
Aug 22, 2023
Glioblastoma Trial in Barcelona, Madrid (Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg)
Not yet recruiting
- Glioblastoma
- Azeliragon 5 mg
- +2 more
-
Barcelona, Spain
- +3 more
Dec 2, 2022
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV) Trial in Baltimore (Chemotherapy with Temodar.,
Terminated
- Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
- Chemotherapy with Temodar.
- Radiation therapy
-
Baltimore, MarylandUmmc Msgcc
Dec 1, 2022
Glioblastoma, Gliosarcoma, Malignant Glioma Trial run by the NCI (TMZ, ipilimumab 3mg/kg, Nivolumab)
Recruiting
- Glioblastoma
- +2 more
- TMZ
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Using Genomic, Histologic and Radiomic Analysis to Evaluate
Suspended
- Glioblastoma
- Tumor Biopsy
-
Ann Arbor, MichiganUniversity of Michigan
Oct 6, 2022
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III Trial in San Antonio, Zuerich (Debio 0123,
Not yet recruiting
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Astrocytoma, Grade III
- Debio 0123
- +2 more
-
San Antonio, Texas
- +1 more
Mar 9, 2023
Glioblastoma, Recurrent Glioblastoma, GBM Trial in Boston (MN-166, Temozolomide)
Active, not recruiting
- Glioblastoma
- +3 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Nov 16, 2022
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma Trial in Fullerton, Newport Beach, Santa Monica (ABI-009,
Active, not recruiting
- High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
- ABI-009
- +5 more
-
Fullerton, California
- +2 more
Jun 13, 2022
Glioblastoma Trial in Oklahoma City (OKN 007, Temozolomide, Photon/Proton IMRT)
Recruiting
- Glioblastoma
- OKN 007
- +2 more
-
Oklahoma City, OklahomaStephenson Cancer Center, University of Oklahoma Health Sciences
Jun 17, 2022
Glioblastoma Trial in Birmingham (Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified
Not yet recruiting
- Glioblastoma
- Autologous genetically modified gamma-delta T cells
- Allogeneic genetically modified gamma-delta T cells
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Dec 16, 2022
Newly-diagnosed Glioblastoma Trial in Beijing (CAN008, Placebo)
Recruiting
- Newly-diagnosed Glioblastoma
- CAN008
- Placebo
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital, Capital Medical University
Jul 10, 2022